Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).

• Role of an hormonal vaginal therapy, the prasterone pessary, in the improvement of the vaginal/vulvar/urinary symptoms in menopausal women w … Recruiting
  2023-506211-18-00 5 2025-01-09

Showing 1–1 of 1 trials